Could a Parent's nose bacteria shield newborns from staph?
NCT ID NCT05695196
First seen Jan 08, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This early study tests whether transferring a parent's healthy nasal bacteria to their newborn can help prevent staph infections. Researchers will give the baby a nasal spray containing the parent's bacteria or a placebo, then monitor the baby's nose bacteria and safety. The study involves 34 infants in the NICU and aims to see if this approach is feasible and safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nasal microbiota transplant (NMT)
What this could lead to
If it works, this could point toward a simple way to protect vulnerable newborns from dangerous staph infections.
What could go wrong
This is a very early Phase 1 trial with only 34 participants, so it may not show clear benefit or could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.